EHS
EHS

LISTEN: A genome-editing flop, a Celgene Senate hopeful, and a live audience

Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma?

We discuss all that and more on a special live (to tape) episode “The Readout LOUD,” STAT’s biotech podcast. In front of a studio audience in Boston, we talk about the first glimpse at how genome editing affects actual humans and the disappointment it brought. Then we take a look at how 2018 has panned out for some of biotech’s hot-button issues, including buyouts, IPOs, and President Trump’s effect on drug prices. We also dive into former Celgene CEO Bob Hugin’s effort to win a Senate race in New Jersey at a time when his industry is widely disliked. And then we embark upon live lightning round, answering questions from members of the audience.

Read the rest…

Source link

EHS
Back to top button